Bladder Cancer Clinical Practice Guideline Diagnosis Evidenced-based Medicine Treatment.

Bladder Cancer Molecular Pathology Guideline

Bladder Cancer Care Consensus

Muscle-invasive Bladder Cancer Management Consensus

Muscle-invasive Bladder Cancer Radiation Therapy Guideline

Bladder Cancer Specimen Pathological Diagnosis Consensus

Bladder Cancer Checkpoint Inhibitors Chemotherapy Immunotherapy Urothelial Cancer

Muscle Invasive Bladder Cancer Consensus

Adjuvant Chemotherapy Bladder-sparing Chemoradiation Enhanced Recovery after Surgery Muscle-invasive Bladder Cancer Neoadjuvant Chemotherapy Radical Cystectomy Transurethral Resection of Bladder Tumor Trimodal Urothelial Carcinoma of Bladder Variant Histology

Muscle-invasive Bladder Cancer Guideline

Delphi Bladder Cancer Consensus Diagnosis Follow-up Treatment

Bladder Cancer Chemotherapy Cystectomy Immune Checkpoint Inhibitors

AUC Appropriate Use Criteria Appropriateness Criteria Bladder Cancer Muscle Invasive Bladder Cancer Nonmuscle Invasive Bladder Cancer Surveillance

Biomarkers/analysis Humans Male MicroRNAs/*analysis Prostatic Hyperplasia/*diagnosis/metabolism Benign prostatic hyperplasia Diagnosis Prostate cancer Therapy miRNA

Urothelial Carcinoma Bladder Cytology Bladder Neoplams Cancer BCG Cystectomy Survival

Bladder Cancer Management Non-muscle-invasive Bladder Cancer Oncology Risk Factors

Bladder Cancer Disease Management Follow-up Guidelines Muscle Invasive

AUC Appropriate Use Criteria Appropriateness Criteria Bladder Cancer CT MRI Muscle-invasive Bladder Cancer Staging Urothelial Carcinoma

Benign Prostatic Hyperplasia Prostate Cancer Bladder Cancer Meta-Analysis

Humans Smoking/adverse effects/epidemiology *Non-Muscle Invasive Bladder Neoplasms *Urinary Bladder Neoplasms/epidemiology/etiology *Carcinoma Transitional Cell Prognosis Neoplasm Recurrence Local/epidemiology Current smoker Non-muscle-invasive bladder cancer Progression Recurrence Smoking